Predicting Risk for Secondary Leukemia after PARPi Therapy Predicting Risk for Secondary Leukemia after PARPi Therapy

A new study pinpointed potential predictive factors for secondary myelodysplastic syndrome or acute myeloid leukemia after PARP inhibitor therapy in women with ovarian cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news